XML 57 R44.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Supplemental Data (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract] |
Condensed Consolidating Statements of Operations | Condensed Consolidating Statements of Operations
|  | DaVita Inc. |  | Guarantor subsidiaries |  | Non- Guarantor subsidiaries |  | Consolidating adjustments |  | Consolidated total
For the three months ended September 30, 2018 |  |  |  |  |
Patient services revenues |  | $ | — |  |  | $ | 1,810,009 |  |  | $ | 914,623 |  |  | $ | (53,931 | ) |  | $ | 2,670,701 |
Provision for uncollectible accounts |  | — |  |  | (8,899 | ) |  | (3,078 | ) |  | — |  |  | (11,977 | )
Net patient service revenues |  | — |  |  | 1,801,110 |  |  | 911,545 |  |  | (53,931 | ) |  | 2,658,724 |
Other revenues |  | 207,968 |  |  | 192,467 |  |  | 36,508 |  |  | (248,337 | ) |  | 188,606 |
Total net revenues |  | 207,968 |  |  | 1,993,577 |  |  | 948,053 |  |  | (302,268 | ) |  | 2,847,330 |
Operating expenses and charges |  | 205,324 |  |  | 1,817,851 |  |  | 837,385 |  |  | (302,268 | ) |  | 2,558,292 |
Operating income |  | 2,644 |  |  | 175,726 |  |  | 110,668 |  |  | — |  |  | 289,038 |
Debt expense |  | (127,353 | ) |  | (52,011 | ) |  | (8,812 | ) |  | 62,249 |  |  | (125,927 | )
Other income, net |  | 106,148 |  |  | 2,339 |  |  | 5,982 |  |  | (110,462 | ) |  | 4,007 |
Income tax (benefit) expense |  | (3,536 | ) |  | 47,977 |  |  | 7,606 |  |  | — |  |  | 52,047 |
Equity earnings in subsidiaries |  | (121,771 | ) |  | 46,972 |  |  | — |  |  | 74,799 |  |  | — |
Net (loss) income from continuing operations |  | (136,796 | ) |  | 125,049 |  |  | 100,232 |  |  | 26,586 |  |  | 115,071 |
Net loss from discontinued operations, net of tax |  | — |  |  | (246,820 | ) |  | (13,132 | ) |  | 48,213 |  |  | (211,739 | )
Net (loss) income |  | (136,796 | ) |  | (121,771 | ) |  | 87,100 |  |  | 74,799 |  |  | (96,668 | )
Less: Net income attributable to noncontrolling interests |  | — |  |  | — |  |  | — |  |  | (40,128 | ) |  | (40,128 | )
Net (loss) income attributable to DaVita Inc. |  | $ | (136,796 | ) |  | $ | (121,771 | ) |  | $ | 87,100 |  |  | $ | 34,671 |  |  | $ | (136,796 | )
|  |  |  | Guarantor subsidiaries |  | Non- Guarantor subsidiaries |  | Consolidating adjustments |  | Consolidated total
For the three months ended September 30, 2017 |  | DaVita Inc. |  |  |  |
Patient service revenues |  | $ | — |  |  | $ | 1,710,708 |  |  | $ | 914,753 |  |  | $ | (63,918 | ) |  | $ | 2,561,543 |
Provision for uncollectible accounts |  | — |  |  | (82,807 | ) |  | (42,649 | ) |  | 6,135 |  |  | (119,321 | )
Net patient service revenues |  | — |  |  | 1,627,901 |  |  | 872,104 |  |  | (57,783 | ) |  | 2,442,222 |
Other revenues |  | 189,275 |  |  | 302,193 |  |  | 11,483 |  |  | (180,102 | ) |  | 322,849 |
Total net revenues |  | 189,275 |  |  | 1,930,094 |  |  | 883,587 |  |  | (237,885 | ) |  | 2,765,071 |
Operating expenses |  | 128,488 |  |  | 1,718,444 |  |  | 760,730 |  |  | (237,885 | ) |  | 2,369,777 |
Operating income |  | 60,787 |  |  | 211,650 |  |  | 122,857 |  |  | — |  |  | 395,294 |
Debt expense |  | (108,453 | ) |  | (48,622 | ) |  | (13,017 | ) |  | 60,786 |  |  | (109,306 | )
Other income |  | 104,250 |  |  | 819 |  |  | 5,941 |  |  | (107,614 | ) |  | 3,396 |
Income tax expense (benefit) |  | 21,199 |  |  | 82,780 |  |  | (13,433 | ) |  | — |  |  | 90,546 |
Equity earnings in subsidiaries |  | (249,861 | ) |  | 89,048 |  |  | — |  |  | 160,813 |  |  | — |
Net (loss) income from continuing operations |  | (214,476 | ) |  | 170,115 |  |  | 129,214 |  |  | 113,985 |  |  | 198,838 |
Net (loss) income from discontinued operations, net of tax |  | — |  |  | (419,976 | ) |  | 2,276 |  |  | 46,828 |  |  | (370,872 | )
Net (loss) income |  | (214,476 | ) |  | (249,861 | ) |  | 131,490 |  |  | 160,813 |  |  | (172,034 | )
Less: Net income attributable to noncontrolling interests |  | — |  |  | — |  |  | — |  |  | (42,442 | ) |  | (42,442 | )
Net (loss) income attributable to DaVita Inc. |  | $ | (214,476 | ) |  | $ | (249,861 | ) |  | $ | 131,490 |  |  | $ | 118,371 |  |  | $ | (214,476 | )
|  | DaVita Inc. |  | Guarantor subsidiaries |  | Non- Guarantor subsidiaries |  | Consolidating adjustments |  | Consolidated total
For the nine months ended September 30, 2018 |  |  |  |  |
Patient service revenues |  | $ | — |  |  | $ | 5,431,742 |  |  | $ | 2,699,670 |  |  | $ | (151,234 | ) |  | $ | 7,980,178 |
Provision for uncollectible accounts |  | — |  |  | (26,430 | ) |  | (9,408 | ) |  | — |  |  | (35,838 | )
Net patient service revenues |  | — |  |  | 5,405,312 |  |  | 2,690,262 |  |  | (151,234 | ) |  | 7,944,340 |
Other revenues |  | 608,850 |  |  | 611,693 |  |  | 150,578 |  |  | (731,734 | ) |  | 639,387 |
Total net revenues |  | 608,850 |  |  | 6,017,005 |  |  | 2,840,840 |  |  | (882,968 | ) |  | 8,583,727 |
Operating expenses |  | 484,329 |  |  | 5,459,322 |  |  | 2,385,128 |  |  | (882,968 | ) |  | 7,445,811 |
Operating income |  | 124,521 |  |  | 557,683 |  |  | 455,712 |  |  | — |  |  | 1,137,916 |
Debt expense |  | (362,501 | ) |  | (156,571 | ) |  | (25,461 | ) |  | 185,398 |  |  | (359,135 | )
Other income |  | 315,573 |  |  | 7,718 |  |  | 16,126 |  |  | (328,834 | ) |  | 10,583 |
Income tax expense |  | 24,108 |  |  | 136,939 |  |  | 45,605 |  |  | — |  |  | 206,652 |
Equity earnings in subsidiaries |  | 255,681 |  |  | 305,823 |  |  | — |  |  | (561,504 | ) |  | — |
Net income from continuing operations |  | 309,166 |  |  | 577,714 |  |  | 400,772 |  |  | (704,940 | ) |  | 582,712 |
Net (loss) income from discontinued operations, net of tax |  | — |  |  | (322,033 | ) |  | 30,768 |  |  | 143,436 |  |  | (147,829 | )
Net income |  | 309,166 |  |  | 255,681 |  |  | 431,540 |  |  | (561,504 | ) |  | 434,883 |
Less: Net income attributable to noncontrolling interests |  | — |  |  | — |  |  | — |  |  | (125,717 | ) |  | (125,717 | )
Net income attributable to DaVita Inc. |  | $ | 309,166 |  |  | $ | 255,681 |  |  | $ | 431,540 |  |  | $ | (687,221 | ) |  | $ | 309,166 |
|  | DaVita Inc. |  | Guarantor subsidiaries |  | Non- Guarantor subsidiaries |  | Consolidating adjustments |  | Consolidated total
For the nine months ended September 30, 2017 |  |  |  |  |
Patient service revenues |  | $ | — |  |  | $ | 4,895,864 |  |  | $ | 2,723,764 |  |  | $ | (140,690 | ) |  | $ | 7,478,938 |
Provision for uncollectible accounts |  | — |  |  | (216,705 | ) |  | (125,409 | ) |  | 6,135 |  |  | (335,979 | )
Net patient service revenues |  | — |  |  | 4,679,159 |  |  | 2,598,355 |  |  | (134,555 | ) |  | 7,142,959 |
Other revenues |  | 604,246 |  |  | 913,130 |  |  | 43,408 |  |  | (608,022 | ) |  | 952,762 |
Total net revenues |  | 604,246 |  |  | 5,592,289 |  |  | 2,641,763 |  |  | (742,577 | ) |  | 8,095,721 |
Operating expenses |  | 398,502 |  |  | 4,609,747 |  |  | 2,167,631 |  |  | (742,577 | ) |  | 6,433,303 |
Operating income |  | 205,744 |  |  | 982,542 |  |  | 474,132 |  |  | — |  |  | 1,662,418 |
Debt expense |  | (317,276 | ) |  | (144,382 | ) |  | (38,287 | ) |  | 178,308 |  |  | (321,637 | )
Other income |  | 306,886 |  |  | 4,991 |  |  | 15,524 |  |  | (315,221 | ) |  | 12,180 |
Income tax expense |  | 75,680 |  |  | 389,945 |  |  | 8,501 |  |  | — |  |  | 474,126 |
Equity earnings in subsidiaries |  | 240,548 |  |  | 337,213 |  |  | — |  |  | (577,761 | ) |  | — |
Net income from continuing operations |  | 360,222 |  |  | 790,419 |  |  | 442,868 |  |  | (714,674 | ) |  | 878,835 |
Net (loss) income from discontinued operations, net of tax |  | — |  |  | (549,871 | ) |  | 23,999 |  |  | 136,913 |  |  | (388,959 | )
Net income |  | 360,222 |  |  | 240,548 |  |  | 466,867 |  |  | (577,761 | ) |  | 489,876 |
Less: Net income attributable to noncontrolling interests |  | — |  |  | — |  |  | — |  |  | (129,654 | ) |  | (129,654 | )
Net income attributable to DaVita Inc. |  | $ | 360,222 |  |  | $ | 240,548 |  |  | $ | 466,867 |  |  | $ | (707,415 | ) |  | $ | 360,222 |
Condensed Consolidating Statements of Income
|  | Consolidated Total |  | Physician Groups |  | Unrestricted Subsidiaries |  | Company and Restricted Subsidiaries(1)
For the nine months ended September 30, 2018 |  |  |  |
Patient service operating revenues |  | $ | 7,980,178 |  |  | $ | — |  |  | $ | — |  |  | $ | 7,980,178 |
Provision for uncollectible accounts |  | (35,838 | ) |  | — |  |  | — |  |  | (35,838 | )
Net patient service operating revenues |  | 7,944,340 |  |  | — |  |  | — |  |  | 7,944,340 |
Other revenues |  | 639,387 |  |  | — |  |  | — |  |  | 639,387 |
Total net operating revenues |  | 8,583,727 |  |  | — |  |  | — |  |  | 8,583,727 |
Operating expenses |  | 7,445,811 |  |  | — |  |  | — |  |  | 7,445,811 |
Operating income |  | 1,137,916 |  |  | — |  |  | — |  |  | 1,137,916 |
Debt expense, including refinancing charges |  | (359,135 | ) |  | — |  |  | — |  |  | (359,135 | )
Other income |  | 10,583 |  |  | — |  |  | — |  |  | 10,583 |
Income tax expense |  | 206,652 |  |  | — |  |  | — |  |  | 206,652 |
Net income from continuing operations |  | 582,712 |  |  | — |  |  | — |  |  | 582,712 |
Net (loss) income from discontinued operations, net of tax |  | (147,829 | ) |  | 20,773 |  |  | 298 |  |  | (168,900 | )
Net income |  | 434,883 |  |  | 20,773 |  |  | 298 |  |  | 413,812 |
Less: Net income attributable to noncontrolling interests |  | (125,717 | ) |  | (6,961 | ) |  | — |  |  | (118,756 | )
Net income attributable to DaVita Inc. |  | $ | 309,166 |  |  | $ | 13,812 |  |  | $ | 298 |  |  | $ | 295,056 |
(1) | After elimination of the unrestricted subsidiaries and the physician groups.
Condensed Consolidating Statements of Comprehensive Income | Condensed Consolidating Statements of Comprehensive Income
|  |  |  | Guarantor subsidiaries |  | Non- Guarantor subsidiaries |  | Consolidating adjustments |  | Consolidated total
For the three months ended September 30, 2018 |  | DaVita Inc. |  |  |  |
Net (loss) income |  | $ | (136,796 | ) |  | $ | (121,771 | ) |  | $ | 87,100 |  |  | $ | 74,799 |  |  | $ | (96,668 | )
Other comprehensive income (loss) |  | 1,643 |  |  | — |  |  | (8,827 | ) |  | — |  |  | (7,184 | )
Total comprehensive (loss) income |  | (135,153 | ) |  | (121,771 | ) |  | 78,273 |  |  | 74,799 |  |  | (103,852 | )
Less: Comprehensive income attributable to noncontrolling interest |  | — |  |  | — |  |  | — |  |  | (40,128 | ) |  | (40,128 | )
Comprehensive (loss) income attributable to DaVita Inc. |  | $ | (135,153 | ) |  | $ | (121,771 | ) |  | $ | 78,273 |  |  | $ | 34,671 |  |  | $ | (143,980 | )
|  |  |  | Guarantor subsidiaries |  | Non- Guarantor subsidiaries |  | Consolidating adjustments |  | Consolidated total
For the three months ended September 30, 2017 |  | DaVita Inc. |  |  |  |
Net (loss) income |  | $ | (214,476 | ) |  | $ | (249,861 | ) |  | $ | 131,490 |  |  | $ | 160,813 |  |  | $ | (172,034 | )
Other comprehensive income |  | 1,641 |  |  | — |  |  | 29,143 |  |  | — |  |  | 30,784 |
Total comprehensive (loss) income |  | (212,835 | ) |  | (249,861 | ) |  | 160,633 |  |  | 160,813 |  |  | (141,250 | )
Less: Comprehensive income attributable to noncontrolling interest |  | — |  |  | — |  |  | — |  |  | (42,442 | ) |  | (42,442 | )
Comprehensive (loss) income attributable to DaVita Inc. |  | $ | (212,835 | ) |  | $ | (249,861 | ) |  | $ | 160,633 |  |  | $ | 118,371 |  |  | $ | (183,692 | )
|  |  |  | Guarantor subsidiaries |  | Non- Guarantor subsidiaries |  | Consolidating adjustments |  | Consolidated total
For the nine months ended September 30, 2018 |  | DaVita Inc. |  |  |  |
Net income |  | $ | 309,166 |  |  | $ | 255,681 |  |  | $ | 431,540 |  |  | $ | (561,504 | ) |  | $ | 434,883 |
Other comprehensive income (loss) |  | 5,499 |  |  | — |  |  | (39,475 | ) |  | — |  |  | (33,976 | )
Total comprehensive income |  | 314,665 |  |  | 255,681 |  |  | 392,065 |  |  | (561,504 | ) |  | 400,907 |
Less: Comprehensive income attributable to noncontrolling interest |  | — |  |  | — |  |  | — |  |  | (125,717 | ) |  | (125,717 | )
Comprehensive income attributable to DaVita Inc. |  | $ | 314,665 |  |  | $ | 255,681 |  |  | $ | 392,065 |  |  | $ | (687,221 | ) |  | $ | 275,190 |
|  |  |  | Guarantor subsidiaries |  | Non- Guarantor subsidiaries |  | Consolidating adjustments |  | Consolidated total
For the nine months ended September 30, 2017 |  | DaVita Inc. |  |  |  |
Net income |  | $ | 360,222 |  |  | $ | 240,548 |  |  | $ | 466,867 |  |  | $ | (577,761 | ) |  | $ | 489,876 |
Other comprehensive income |  | 1,571 |  |  | — |  |  | 91,546 |  |  | — |  |  | 93,117 |
Total comprehensive income |  | 361,793 |  |  | 240,548 |  |  | 558,413 |  |  | (577,761 | ) |  | 582,993 |
Less: Comprehensive income attributable to noncontrolling interest |  | — |  |  | — |  |  | — |  |  | (129,652 | ) |  | (129,652 | )
Comprehensive income attributable to DaVita Inc. |  | $ | 361,793 |  |  | $ | 240,548 |  |  | $ | 558,413 |  |  | $ | (707,413 | ) |  | $ | 453,341 |
Condensed Consolidating Statements of Comprehensive Income
|  | Consolidated Total |  | Physician Groups |  | Unrestricted Subsidiaries |  | Company and Restricted Subsidiaries(1)
For the nine months ended September 30, 2018 |  |  |  |
Net income |  | $ | 434,883 |  |  | $ | 20,773 |  |  | $ | 298 |  |  | $ | 413,812 |
Other comprehensive loss |  | (33,976 | ) |  | — |  |  | — |  |  | (33,976 | )
Total comprehensive income |  | 400,907 |  |  | 20,773 |  |  | 298 |  |  | 379,836 |
Less: Comprehensive income attributable to the noncontrolling interests |  | (125,717 | ) |  | (6,961 | ) |  | — |  |  | (118,756 | )
Comprehensive income attributable to DaVita Inc. |  | $ | 275,190 |  |  | $ | 13,812 |  |  | $ | 298 |  |  | $ | 261,080 |
(1) | After elimination of the unrestricted subsidiaries and the physician groups.
Condensed Consolidating Balance Sheets | Condensed Consolidating Balance Sheets
|  |  |  | Guarantor subsidiaries |  | Non- Guarantor subsidiaries |  | Consolidating adjustments |  | Consolidated total
As of September 30, 2018 |  | DaVita Inc. |  |  |  |
Cash and cash equivalents |  | $ | 296,697 |  |  | $ | — |  |  | $ | 151,518 |  |  | $ | — |  |  | $ | 448,215 |
Restricted cash and equivalents |  | 1,004 |  |  | 11,985 |  |  | 78,951 |  |  | — |  |  | 91,940 |
Accounts receivable, net |  | — |  |  | 1,241,147 |  |  | 605,939 |  |  | — |  |  | 1,847,086 |
Other current assets |  | 37,185 |  |  | 467,669 |  |  | 89,620 |  |  | — |  |  | 594,474 |
Current assets held for sale, net |  | — |  |  | 4,999,748 |  |  | 948,038 |  |  | — |  |  | 5,947,786 |
Total current assets |  | 334,886 |  |  | 6,720,549 |  |  | 1,874,066 |  |  | — |  |  | 8,929,501 |
Property and equipment, net |  | 466,162 |  |  | 1,563,552 |  |  | 1,245,922 |  |  | — |  |  | 3,275,636 |
Intangible assets, net |  | 176 |  |  | 43,704 |  |  | 53,729 |  |  | — |  |  | 97,609 |
Investments in subsidiaries |  | 10,071,347 |  |  | 3,164,083 |  |  | — |  |  | (13,235,430 | ) |  | — |
Intercompany receivables |  | 3,496,240 |  |  | — |  |  | 1,478,557 |  |  | (4,974,797 | ) |  | — |
Other long-term assets and investments |  | 54,853 |  |  | 86,821 |  |  | 210,710 |  |  | — |  |  | 352,384 |
Goodwill |  | — |  |  | 4,778,542 |  |  | 1,924,117 |  |  | — |  |  | 6,702,659 |
Total assets |  | $ | 14,423,664 |  |  | $ | 16,357,251 |  |  | $ | 6,787,101 |  |  | $ | (18,210,227 | ) |  | $ | 19,357,789 |
Current liabilities |  | $ | 1,815,234 |  |  | $ | 1,149,518 |  |  | $ | 470,731 |  |  | $ | — |  |  | $ | 3,435,483 |
Current liabilities held for sale |  | — |  |  | 892,548 |  |  | 527,073 |  |  | — |  |  | 1,419,621 |
Intercompany payables |  | — |  |  | 3,485,322 |  |  | 1,489,475 |  |  | (4,974,797 | ) |  | — |
Long-term debt and other long-term liabilities |  | 8,186,683 |  |  | 758,516 |  |  | 463,812 |  |  | — |  |  | 9,409,011 |
Noncontrolling interests subject to put provisions |  | 597,098 |  |  | — |  |  | — |  |  | 467,314 |  |  | 1,064,412 |
Total DaVita Inc. shareholders' equity |  | 3,824,649 |  |  | 10,071,347 |  |  | 3,164,083 |  |  | (13,235,430 | ) |  | 3,824,649 |
Noncontrolling interests not subject to put provisions |  | — |  |  | — |  |  | 671,927 |  |  | (467,314 | ) |  | 204,613 |
Total equity |  | 3,824,649 |  |  | 10,071,347 |  |  | 3,836,010 |  |  | (13,702,744 | ) |  | 4,029,262 |
Total liabilities and equity |  | $ | 14,423,664 |  |  | $ | 16,357,251 |  |  | $ | 6,787,101 |  |  | $ | (18,210,227 | ) |  | $ | 19,357,789 |
|  |  |  | Guarantor subsidiaries |  | Non- Guarantor subsidiaries |  | Consolidating adjustments |  | Consolidated total
As of December 31, 2017 |  | DaVita Inc. |  |  |  |
Cash and cash equivalents |  | $ | 149,305 |  |  | $ | — |  |  | $ | 358,929 |  |  | $ | — |  |  | $ | 508,234 |
Restricted cash and equivalents |  | 1,002 |  |  | 9,384 |  |  | 300 |  |  | — |  |  | 10,686 |
Accounts receivable, net |  | — |  |  | 1,208,715 |  |  | 506,035 |  |  | — |  |  | 1,714,750 |
Other current assets |  | 67,025 |  |  | 595,066 |  |  | 86,955 |  |  | — |  |  | 749,046 |
Current assets held for sale |  | — |  |  | 4,992,067 |  |  | 769,575 |  |  | — |  |  | 5,761,642 |
Total current assets |  | 217,332 |  |  | 6,805,232 |  |  | 1,721,794 |  |  | — |  |  | 8,744,358 |
Property and equipment, net |  | 408,010 |  |  | 1,560,390 |  |  | 1,180,813 |  |  | — |  |  | 3,149,213 |
Intangible assets, net |  | 250 |  |  | 50,971 |  |  | 62,606 |  |  | — |  |  | 113,827 |
Investments in subsidiaries |  | 10,009,874 |  |  | 3,085,722 |  |  | — |  |  | (13,095,596 | ) |  | — |
Intercompany receivables |  | 3,677,947 |  |  | — |  |  | 1,313,213 |  |  | (4,991,160 | ) |  | — |
Other long-term assets and investments |  | 47,297 |  |  | 68,344 |  |  | 214,875 |  |  | — |  |  | 330,516 |
Goodwill |  | — |  |  | 4,732,320 |  |  | 1,877,959 |  |  | — |  |  | 6,610,279 |
Total assets |  | $ | 14,360,710 |  |  | $ | 16,302,979 |  |  | $ | 6,371,260 |  |  | $ | (18,086,756 | ) |  | $ | 18,948,193 |
Current liabilities |  | $ | 238,706 |  |  | $ | 1,181,139 |  |  | $ | 436,262 |  |  | $ | — |  |  | $ | 1,856,107 |
Current liabilities held for sale |  | — |  |  | 739,294 |  |  | 445,776 |  |  | — |  |  | 1,185,070 |
Intercompany payables |  | — |  |  | 3,690,042 |  |  | 1,301,118 |  |  | (4,991,160 | ) |  | — |
Long-term debt and other long-term liabilities |  | 8,857,373 |  |  | 682,630 |  |  | 469,587 |  |  | — |  |  | 10,009,590 |
Noncontrolling interests subject to put provisions |  | 574,602 |  |  | — |  |  | — |  |  | 436,758 |  |  | 1,011,360 |
Total DaVita Inc. shareholders' equity |  | 4,690,029 |  |  | 10,009,874 |  |  | 3,085,722 |  |  | (13,095,596 | ) |  | 4,690,029 |
Noncontrolling interests not subject to put provisions |  | — |  |  | — |  |  | 632,795 |  |  | (436,758 | ) |  | 196,037 |
Total equity |  | 4,690,029 |  |  | 10,009,874 |  |  | 3,718,517 |  |  | (13,532,354 | ) |  | 4,886,066 |
Total liabilities and equity |  | $ | 14,360,710 |  |  | $ | 16,302,979 |  |  | $ | 6,371,260 |  |  | $ | (18,086,756 | ) |  | $ | 18,948,193 |
Condensed Consolidating Balance Sheets
|  | Consolidated Total |  | Physician Groups |  | Unrestricted Subsidiaries |  | Company and Restricted Subsidiaries(1)
As of September 30, 2018 |  |  |  |
Cash and cash equivalents |  | $ | 448,215 |  |  | $ | — |  |  | $ | — |  |  | $ | 448,215 |
Restricted cash and equivalents |  | 91,940 |  |  | — |  |  | — |  |  | 91,940 |
Accounts receivable, net |  | 1,847,086 |  |  | — |  |  | — |  |  | 1,847,086 |
Other current assets |  | 594,474 |  |  | — |  |  | — |  |  | 594,474 |
Current assets held for sale, net |  | 5,947,786 |  |  | 567,216 |  |  | 3,031 |  |  | 5,377,539 |
Total current assets |  | 8,929,501 |  |  | 567,216 |  |  | 3,031 |  |  | 8,359,254 |
Property and equipment, net |  | 3,275,636 |  |  | — |  |  | — |  |  | 3,275,636 |
Amortizable intangibles, net |  | 97,609 |  |  | — |  |  | — |  |  | 97,609 |
Other long-term assets |  | 352,384 |  |  | — |  |  | — |  |  | 352,384 |
Goodwill |  | 6,702,659 |  |  | — |  |  | — |  |  | 6,702,659 |
Total assets |  | $ | 19,357,789 |  |  | $ | 567,216 |  |  | $ | 3,031 |  |  | $ | 18,787,542 |
Current liabilities |  | $ | 3,435,483 |  |  | $ | — |  |  | $ | — |  |  | $ | 3,435,483 |
Current liabilities held for sale |  | 1,419,621 |  |  | 350,640 |  |  | — |  |  | 1,068,981 |
Payables to parent |  | — |  |  | 78,496 |  |  | 3,031 |  |  | (81,527 | )
Long-term debt and other long-term liabilities |  | 9,409,011 |  |  | — |  |  | — |  |  | 9,409,011 |
Noncontrolling interests subject to put provisions |  | 1,064,412 |  |  | — |  |  | — |  |  | 1,064,412 |
Total DaVita Inc. shareholders’ equity |  | 3,824,649 |  |  | 138,080 |  |  | — |  |  | 3,686,569 |
Noncontrolling interests not subject to put provisions |  | 204,613 |  |  | — |  |  | — |  |  | 204,613 |
Shareholders’ equity |  | 4,029,262 |  |  | 138,080 |  |  | — |  |  | 3,891,182 |
Total liabilities and shareholder’s equity |  | $ | 19,357,789 |  |  | $ | 567,216 |  |  | $ | 3,031 |  |  | $ | 18,787,542 |
(1) | After elimination of the unrestricted subsidiaries and the physician groups.
Condensed Consolidating Statements of Cash Flows | Condensed Consolidating Statements of Cash Flows
|  |  |  | Guarantor subsidiaries |  | Non- Guarantor subsidiaries |  | Consolidating adjustments |  | Consolidated total
For the nine months ended September 30, 2018 |  | DaVita Inc. |  |  |  |
Cash flows from operating activities: |  |  |  |  |  |  |  |  |  |
Net income |  | $ | 309,166 |  |  | $ | 255,681 |  |  | $ | 431,540 |  |  | $ | (561,504 | ) |  | $ | 434,883 |
Changes in operating assets and liabilities and non-cash items included in net income |  | (235,558 | ) |  | 469,008 |  |  | 152,411 |  |  | 561,504 |  |  | 947,365 |
Net cash provided by operating activities |  | 73,608 |  |  | 724,689 |  |  | 583,951 |  |  | — |  |  | 1,382,248 |
Cash flows from investing activities: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Additions of property and equipment |  | (124,585 | ) |  | (385,765 | ) |  | (195,309 | ) |  | — |  |  | (705,659 | )
Acquisitions |  | — |  |  | (18,549 | ) |  | (94,977 | ) |  | — |  |  | (113,526 | )
Proceeds from asset and business sales |  | — |  |  | 47,025 |  |  | 88,243 |  |  | — |  |  | 135,268 |
Proceeds (purchases) from investment sales and other items, net |  | 32,345 |  |  | (9,746 | ) |  | (1 | ) |  | — |  |  | 22,598 |
Net cash used in investing activities |  | (92,240 | ) |  | (367,035 | ) |  | (202,044 | ) |  | — |  |  | (661,319 | )
Cash flows from financing activities: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Long-term debt and related financing costs, net |  | 866,537 |  |  | (9,135 | ) |  | (11,566 | ) |  | — |  |  | 845,836 |
Intercompany borrowing (payments) |  | 454,410 |  |  | (217,518 | ) |  | (236,892 | ) |  | — |  |  | — |
Other items |  | (1,154,921 | ) |  | (94,281 | ) |  | (19,973 | ) |  | — |  |  | (1,269,175 | )
Net cash provided by (used in) financing activities |  | 166,026 |  |  | (320,934 | ) |  | (268,431 | ) |  | — |  |  | (423,339 | )
Effect of exchange rate changes on cash, cash equivalents and restricted cash |  | — |  |  | — |  |  | (5,790 | ) |  | — |  |  | (5,790 | )
Net increase in cash, cash equivalents and restricted cash |  | 147,394 |  |  | 36,720 |  |  | 107,686 |  |  | — |  |  | 291,800 |
Less: Net increase in cash, cash equivalents and restricted cash from discontinued operations |  | — |  |  | 34,119 |  |  | 236,446 |  |  | — |  |  | 270,565 |
Net increase (decrease) in cash, cash equivalents and restricted cash from continuing operations |  | 147,394 |  |  | 2,601 |  |  | (128,760 | ) |  | — |  |  | 21,235 |
Cash, cash equivalents and restricted cash of continuing operations at beginning of the year |  | 150,307 |  |  | 9,384 |  |  | 359,229 |  |  | — |  |  | 518,920 |
Cash, cash equivalents and restricted cash of continuing operations at end of the period |  | $ | 297,701 |  |  | $ | 11,985 |  |  | $ | 230,469 |  |  | $ | — |  |  | $ | 540,155 |
|  |  |  | Guarantor subsidiaries |  | Non- Guarantor subsidiaries |  | Consolidating adjustments |  | Consolidated total
For the nine months ended September 30, 2017 |  | DaVita Inc. |  |  |  |
Cash flows from operating activities: |  |  |  |  |  |  |  |  |  |
Net income |  | $ | 360,222 |  |  | $ | 240,548 |  |  | $ | 466,867 |  |  | $ | (577,761 | ) |  | $ | 489,876 |
Changes in operating assets and liabilities and non-cash items included in net income |  | (282,651 | ) |  | 585,836 |  |  | 197,328 |  |  | 577,761 |  |  | 1,078,274 |
Net cash provided by operating activities |  | 77,571 |  |  | 826,384 |  |  | 664,195 |  |  | — |  |  | 1,568,150 |
Cash flows from investing activities: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Additions of property and equipment |  | (94,385 | ) |  | (305,261 | ) |  | (240,183 | ) |  | — |  |  | (639,829 | )
Acquisitions |  | — |  |  | (627,324 | ) |  | (99,214 | ) |  | — |  |  | (726,538 | )
Proceeds from asset and business sales |  | — |  |  | 90,533 |  |  | 1,996 |  |  | — |  |  | 92,529 |
Proceeds (purchases) from investment sales and other items, net |  | 123,894 |  |  | (4,788 | ) |  | 49,183 |  |  | — |  |  | 168,289 |
Net cash provided by (used in) investing activities |  | 29,509 |  |  | (846,840 | ) |  | (288,218 | ) |  | — |  |  | (1,105,549 | )
Cash flows from financing activities: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Long-term debt and related financing costs, net |  | (92,721 | ) |  | (10,394 | ) |  | (5,348 | ) |  | — |  |  | (108,463 | )
Intercompany borrowing (payments) |  | 188,977 |  |  | (7,968 | ) |  | (181,009 | ) |  | — |  |  | — |
Other items |  | (305,630 | ) |  | (1,432 | ) |  | (114,307 | ) |  | — |  |  | (421,369 | )
Net cash used in financing activities |  | (209,374 | ) |  | (19,794 | ) |  | (300,664 | ) |  | — |  |  | (529,832 | )
Effect of exchange rate changes on cash, cash equivalents and restricted cash |  | — |  |  | — |  |  | 5,449 |  |  | — |  |  | 5,449 |
Net decrease in cash, cash equivalents and restricted cash |  | (102,294 | ) |  | (40,250 | ) |  | 80,762 |  |  | — |  |  | (61,782 | )
Less: Net increase (decrease) in cash, cash equivalents and restricted cash from discontinued operations |  | — |  |  | (41,934 | ) |  | 124,628 |  |  | — |  |  | 82,694 |
Net increase (decrease) in cash, cash equivalents and restricted cash from continuing operations |  | (102,294 | ) |  | 1,684 |  |  | (43,866 | ) |  | — |  |  | (144,476 | )
Cash, cash equivalents and restricted cash of continuing operations at beginning of the year |  | 549,921 |  |  | 8,687 |  |  | 124,855 |  |  | — |  |  | 683,463 |
Cash, cash equivalents and restricted cash of continuing operations at end of the period |  | $ | 447,627 |  |  | $ | 10,371 |  |  | $ | 80,989 |  |  | $ | — |  |  | $ | 538,987 |
Condensed Consolidating Statements of Cash Flows
|  | Consolidated Total |  | Physician Groups |  | Unrestricted Subsidiaries |  | Company and Restricted Subsidiaries(1)
For the nine months ended September 30, 2018 |  |  |  |
Cash flows from operating activities: |  |  |  |  |  |  |  |
Net income |  | $ | 434,883 |  |  | $ | 20,773 |  |  | $ | 298 |  |  | $ | 413,812 |
Changes in operating and intercompany assets and liabilities and non-cash items included in net income |  | 947,365 |  |  | 77,229 |  |  | (298 | ) |  | 870,434 |
Net cash provided by operating activities |  | 1,382,248 |  |  | 98,002 |  |  | — |  |  | 1,284,246 |
Cash flows from investing activities: |  |  |  |  |  |  |  |  |  |  |  |
Additions of property and equipment |  | (705,659 | ) |  | (2,575 | ) |  | — |  |  | (703,084 | )
Acquisitions |  | (113,526 | ) |  | — |  |  | — |  |  | (113,526 | )
Proceeds from asset and business sales |  | 135,268 |  |  | — |  |  | — |  |  | 135,268 |
Investments and other items |  | 22,598 |  |  | (1 | ) |  | — |  |  | 22,599 |
Net cash used in investing activities |  | (661,319 | ) |  | (2,576 | ) |  | — |  |  | (658,743 | )
Cash flows from financing activities: |  |  |  |  |  |  |  |  |  |  |  |
Long-term debt |  | 845,836 |  |  | — |  |  | — |  |  | 845,836 |
Intercompany |  | — |  |  | 77,286 |  |  | — |  |  | (77,286 | )
Other items |  | (1,269,175 | ) |  | — |  |  | — |  |  | (1,269,175 | )
Net cash (used in) provided by financing activities |  | (423,339 | ) |  | 77,286 |  |  | — |  |  | (500,625 | )
Effect of exchange rate changes on cash, cash equivalents and restricted cash |  | (5,790 | ) |  | — |  |  | — |  |  | (5,790 | )
Net increase in cash, cash equivalents and restricted cash |  | 291,800 |  |  | 172,712 |  |  | — |  |  | 119,088 |
Less: Net increase in cash, cash equivalents and restricted cash from discontinued operations |  | 270,565 |  |  | 172,712 |  |  | — |  |  | 97,853 |
Net increase in cash, cash equivalents and restricted cash from continuing operations |  | 21,235 |  |  | — |  |  | — |  |  | 21,235 |
Cash, cash equivalents and restricted cash of continuing operations at beginning of the year |  | 518,920 |  |  | — |  |  | — |  |  | 518,920 |
Cash, cash equivalents and restricted cash of continuing operations at end of the period |  | $ | 540,155 |  |  | $ | — |  |  | $ | — |  |  | $ | 540,155 |
(1) | After elimination of the unrestricted subsidiaries and the physician groups.

X
- Definition Tabular disclosure of condensed statement of comprehensive income (loss) including, but not limited to, statements of comprehensive income (loss) of consolidated entities and consolidation eliminations. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 3 -Paragraph i -Subsection 10 + Details
Name: | srt_CondensedStatementOfComprehensiveIncomeTableTextBlock
Namespace Prefix: | srt_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of condensed balance sheet, including, but not limited to, balance sheets of consolidated entities and consolidation eliminations. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 3 -Paragraph i -Subsection 10 + Details
Name: | srt_ScheduleOfCondensedBalanceSheetTableTextBlock
Namespace Prefix: | srt_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of condensed cash flow statement, including, but not limited to, cash flow statements of consolidated entities and consolidation eliminations. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 3 -Paragraph i -Subsection 10 + Details
Name: | srt_ScheduleOfCondensedCashFlowStatementTableTextBlock
Namespace Prefix: | srt_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of condensed income statement, including, but not limited to, income statements of consolidated entities and consolidation eliminations. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 3 -Paragraph i -Subsection 10 + Details
Name: | srt_ScheduleOfCondensedIncomeStatementTableTextBlock
Namespace Prefix: | srt_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration